Roivant Sciences (ROIV) EBITDA (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of EBITDA data on file, last reported at -$930.3 million in Q4 2025.

• Quarterly EBITDA fell 29.51% year-over-year to -$930.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.2 billion (down 156.49% YoY) and the FY2026 annual result came in at -$515.1 million, up 48.66% from the prior year.
• EBITDA declined to -$930.3 million in Q4 2025, from -$306.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $5.1 billion in Q4 2023 to a low of -$1.1 billion in Q4 2021.
• A 5-year average of -$98.3 million and a median of -$284.9 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2021 — EBITDA plunged 337.22% — and 2023, when it jumped 644.81%.
• Tracing ROIV's EBITDA over 5 years: stood at -$1.1 billion in 2021, then grew by 13.25% to -$941.2 million in 2022, then jumped by 644.81% to $5.1 billion in 2023, then tumbled by 114.01% to -$718.3 million in 2024, then fell by 29.51% to -$930.3 million in 2025.
• The last three EBITDA figures came in at -$930.3 million (Q4 2025), -$306.2 million (Q3 2025), and -$284.9 million (Q2 2025), per Business Quant data.